Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Diabetes Reports
Published in: Current Diabetes Reports 5/2012

01-10-2012 | Transplantation (A Pileggi, Section Editor)

Recovery of Endocrine Function After Islet and Pancreas Transplantation

Author: Michael R. Rickels

Published in: Current Diabetes Reports | Issue 5/2012

Login to get access

Abstract

Long-standing type 1 diabetes (T1D) is associated with an absolute loss of endogenous insulin secretion (circulating C-peptide is undetectable) and a related defect in glucose counter-regulation that is often complicated by hypoglycemia unawareness, markedly increasing the risk for severe hypoglycemia. Both the transplantation of isolated islets and a whole pancreas can restore β-cell secretory capacity, improve glucose counter-regulation, and return hypoglycemia awareness, thus alleviating severe hypoglycemia. The transplantation of islets may require more than one donor pancreas, and the recovery of endocrine function for now appears more durable with a whole pancreas; however, islet transplantation outcomes are steadily improving. Because not all patients with T1D experiencing severe hypoglycemia are candidates to receive a whole pancreas, and since not all pancreata are technically suitable for whole organ transplantation, islet and pancreas transplantation are evolving as complementary approaches for the recovery of endocrine function in patients with the most problematic T1D.
Literature
1.
• Ludwig B, Ludwig S, Steffen A, Saeger HD, Bornstein SR. Islet vs pancreas transplantation in type 1 diabetes: competitive or complementary? Curr Diab Rep. 2010;10:506–11. This review discusses the current indications for islet and pancreas transplantation as treatments for T1D.PubMedCrossRef
2.
Frank A, Deng SP, Huang XL, et al. Transplantation for type 1 diabetes - Comparison of vascularized whole-organ pancreas with isolated pancreatic islets. Ann Surg. 2004;240:631–40.PubMed
3.
Gruessner AC, Sutherland DE. Pancreas transplant outcomes for United States (US) and non-US cases as reported to the United Network for Organ Sharing (UNOS) and the International Pancreas Transplant Registry (IPTR) as of June 2004. Clin Transplant. 2005;19:433–55.PubMedCrossRef
4.
•• Barton FB, Rickels MR, Alejandro R, et al. Improvement in outcomes of clinical islet transplantation: 1999–2010. Diabetes Care. 2012;35:1436–45. This most recent report from the Collaborative Islet Transplant Registry describes the progress in achieving key metabolic outcomes balanced against safety over the last decade.
5.
• So llinger HW, Odorico JS, Becker YT, D'Alessandro AM, Pirsch JD. One thousand simultaneous pancreas-kidney transplants at a single center with 22-year follow-up. Ann Surg. 2009;250:618–30. An impressive accounting of the "gold-standard" approach to the recovery of endocrine function in advanced T1D complicated by end-stage nephropathy.PubMed
6.
• Gruessner AC, Sutherland DE, Gruessner RW. Long-term outcome after pancreas transplantation. Curr Opin Organ Transplant. 2012;17:100–5. This most recent report from the International Pancreas Transplant Registry provides 10 year outcomes for the various approaches to whole pancreas transplantation and highlights the importance of donor organ selection for achieving long-term benefit.PubMedCrossRef
7.
Larsen MO, Rolin B, Sturis J, et al. Measurements of insulin responses as predictive markers of pancreatic beta–cell mass in normal and beta-cell-reduced lean and obese Gottingen minipigs in vivo. Am J Physiol Endocrinol Metab. 2006;290:E670–7.PubMedCrossRef
8.
Seaquist ER, Robertson RP. Effects of hemipancreatectomy on pancreatic alpha and beta cell function in healthy human donors. J Clin Invest. 1992;89:1761–6.PubMedCrossRef
9.
Christiansen E, Tibell A, Volund A, et al. Pancreatic endocrine function in recipients of segmental and whole pancreas transplantation. J Clin Endocrinol Metab. 1996;81:3972–9.PubMedCrossRef
10.
Robertson RP, Sutherland DE, Lanz KJ. Normoglycemia and preserved insulin secretory reserve in diabetic patients 10–18 years after pancreas transplantation. Diabetes. 1999;48:1737–40.PubMedCrossRef
11.
Robertson RP. Consequences on beta-cell function and reserve after long-term pancreas transplantation. Diabetes. 2004;53:633–44.PubMedCrossRef
12.
Teuscher AU, Kendall DM, Smets YF, Leone JP, Sutherland DE, Robertson RP. Successful islet autotransplantation in humans: functional insulin secretory reserve as an estimate of surviving islet cell mass. Diabetes. 1998;47:324–30.PubMedCrossRef
13.
Greenbaum CJ, Prigeon RL, D'Alessio DA. Impaired beta-cell function, incretin effect, and glucagon suppression in patients with type 1 diabetes who have normal fasting glucose. Diabetes. 2002;51:951–7.PubMedCrossRef
14.
Keymeulen B, Vandemeulebroucke E, Ziegler AG, et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med. 2005;352:2598–608.PubMedCrossRef
15.
The DCCT Research Group. Effects of age, duration and treatment of insulin-dependent diabetes mellitus on residual beta-cell function: observations during eligibility testing for the Diabetes Control and Complications Trial (DCCT). J Clin Endocrinol Metab. 1987;65:30–6.CrossRef
16.
The Diabetes Control and Complications Trial Research Group. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. Ann Intern Med. 1998;128:517–23.
17.
Tsai EB, Sherry NA, Palmer JP, Herold KC. The rise and fall of insulin secretion in type 1 diabetes mellitus. Diabetologia. 2006;49:261–70.PubMedCrossRef
18.
Steffes MW, Sibley S, Jackson M, Thomas W. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care. 2003;26:832–6.PubMedCrossRef
19.
The Diabetes. Control and Complications Trial Research Group. Hypoglycemia in the diabetes control and complications trial. Diabetes. 1997;46:271–86.CrossRef
20.
Fukuda M, Tanaka A, Tahara Y, et al. Correlation between minimal secretory capacity of pancreatic beta-cells and stability of diabetic control. Diabetes. 1988;37:81–8.PubMedCrossRef
21.
22.
Faradji RN, Monroy K, Messinger S, et al. Simple measures to monitor beta-cell mass and assess islet graft dysfunction. Am J Transplant. 2007;7:303–8.PubMedCrossRef
23.
• Shapiro AM. State of the art of clinical islet transplantation and novel protocols of immunosuppression. Curr Diab Rep. 2011;11:345–54. This review discusses the current approach to clinical islet transplantation including the use of novel immunosuppression protocols aimed at increasing the rates of insulin-independence with islets isolated from a single donor.PubMedCrossRef
24.
Kaufman DB, Morel P, Field MJ, Munn SR, Sutherland DER. Purified canine islet autografts–functional outcome as influenced by islet number and implantation site. Transplantation. 1990;50:385–91.PubMedCrossRef
25.
Andersson A, Korsgren O, Jansson L. Intraportally transplanted pancreatic-islets revascularized from hepatic arterial system. Diabetes. 1989;38:192–5.PubMedCrossRef
26.
Faradji RN, Monroy K, Cure P, et al. C-peptide and glucose values in the peritransplant period after intraportal islet infusions in type 1 diabetes. Transplant Proc. 2005;37:3433–4.PubMedCrossRef
27.
Hirshberg B, Mog S, Patterson N, Leconte J, Harlan DM. Histopathological study of intrahepatic islets transplanted in the nonhuman primate model using Edmonton protocol immunosuppression. J Clin Endocrinol Metab. 2002;87:5424–9.PubMedCrossRef
28.
Davalli AM, Ricordi C, Socci C, et al. Abnormal sensitivity to glucose of human islets cultured in a high glucose medium: partial reversibility after an additional culture in a normal glucose medium. J Clin Endocrinol Metab. 1991;72:202–8.PubMedCrossRef
29.
Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in 7 patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med. 2000;343:230–8.PubMedCrossRef
30.
Shapiro AMJ, Ricordi C, Hering BJ, et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med. 2006;355:1318–30.PubMedCrossRef
31.
Ryan EA, Shandro T, Green K, et al. Assessment of the severity of hypoglycemia and glycemic lability in type 1 diabetic subjects undergoing islet transplantation. Diabetes. 2004;53:955–62.PubMedCrossRef
32.
Rickels MR, Schutta MH, Markmann JF, Barker CF, Naji A, Teff KL. Beta-cell function following human islet transplantation for type 1 diabetes. Diabetes. 2005;54:100–6.PubMedCrossRef
33.
Paty BW, Imes S, Ryan EA, Senior PA, Robertson RP, Shapiro AMJ. Insulin secretory reserve as a measure of functional islet mass following islet allotransplantation in type 1 diabetes [abstract]. Diabetes. 2004;53 Suppl 2:A35–6.
34.
Keymeulen B, Gillard P, Mathieu C, et al. Correlation between beta cell mass and glycemic control in type 1 diabetic recipients of islet cell graft. Proc Nat Acad Sci U S A. 2006;103:17444–9.CrossRef
35.
•• Eriksson O, Eich T, Sundin A, et al. Positron emission tomography in clinical islet transplantation. Am J Transplant. 2009;9:2816–24. Using 18F-fluorodeoxyglucose labeled islets in clinical transplantation, this study demonstrates by PET/CT the heterogeneous distribution of intraportally infused islets within the liver and estimates ~ 25% early post-transplant islet loss.PubMedCrossRef
36.
Rickels MR, Naji A, Teff KL. Insulin sensitivity, glucose effectiveness, and free fatty acid dynamics after human islet transplantation for type 1 diabetes. J Clin Endocrinol Metab. 2006;91:2138–44.PubMedCrossRef
37.
Hirsch D, Odorico J, Radke N, et al. Correction of insulin sensitivity and glucose disposal after pancreatic islet transplantation: preliminary results. Diabetes Obes Metab. 2010;12:994–1003.PubMedCrossRef
38.
Lopez-Talavera JC, Garcia-Ocana A, Sipula I, Takane KK, Cozar-Castellano I, Stewart AF. Hepatocyte growth factor gene therapy for pancreatic islets in diabetes: reducing the minimal islet transplant mass required in a glucocorticoid-free rat model of allogeneic portal vein islet transplantation. Endocrinology. 2004;145:467–74.PubMedCrossRef
39.
•• Rickels MR, Mueller R, Teff KL, Naji A. Beta-cell secretory capacity and demand in recipients of islet, pancreas, and kidney transplants. J Clin Endocrinol Metab. 2010;95:1238–46. Using glucose-potentiation of arginine-induced insulin secretion to measure β-cell secretory capacity and demand in islet, pancreas-kidney and kidney transplant groups compared with carefully selected normal and kidney donor control groups, this study evidences that the impaired β-cell secretory capacity seen in islet and not pancreas recipients is best explained by a low engrafted β-cell mass and not by a deleterious effect of tacrolimus.PubMedCrossRef
40.
Soleimanpour SA, Hirshberg B, Bunnell DJ, et al. Metabolic function of a suboptimal transplanted islet mass in non-human primates on rapamycin monotherapy. Cell Transplant. 2011. doi:10.​3727/​096368911X603620​.
41.
Seaquist ER, Kahn SE, Clark PM, Hales CN, Porte D, Robertson RP. Hyperproinsulinemia is associated with increased beta cell demand after hemipancreatectomy in humans. J Clin Invest. 1996;97:455–60.PubMedCrossRef
42.
McDonald CG, Ryan EA, Paty BW, et al. Cross-sectional and prospective association between proinsulin secretion and graft function after clinical islet transplantation. Transplantation. 2004;78:934–7.PubMedCrossRef
43.
Klimek AM, Soukhatcheva G, Thompson DM, et al. Impaired proinsulin processing is a characteristic of transplanted islets. Am J Transplant. 2009;9:2119–25.PubMedCrossRef
44.
Hostens K, Ling ZD, Van Schravendijk C, Pipeleers D. Prolonged exposure of human beta-cells to high glucose increases their release of proinsulin during acute stimulation with glucose or arginine. J Clin Endocrinol Metab. 1999;84:1386–90.PubMedCrossRef
45.
46.
Westermark GT, Westermark P, Berne C, Korsgren O. Widespread amyloid deposition in transplanted human pancreatic islets. N Engl J Med. 2008;359:977–9.PubMedCrossRef
47.
• Westermark GT, Davalli AM, Secchi A, et al. Further evidence for amyloid deposition in clinical pancreatic islet grafts. Transplantation. 2012;93:219–23. This follow-up autopsy study to the initial case report now documents intrahepatic islet amyloid affecting 3 out of 4 transplant recipients, and so suggests islet amyloidosis as a potential contributor to non-immunologic clinical islet graft loss.PubMedCrossRef
48.
Ritzel RA, Meier JJ, Lin CY, Veldhuis JD, Butler PC. Human islet amyloid polypeptide oligomers disrupt cell coupling, induce apoptosis, and impair insulin secretion in isolated human islets. Diabetes. 2007;56:65–71.PubMedCrossRef
49.
Kahn SE, Dalessio DA, Schwartz MW, et al. Evidence of cosecretion of islet amyloid polypeptide and insulin by beta-cells. Diabetes. 1990;39:634–8.PubMedCrossRef
50.
Westermark P, Li ZC, Westermark GT, Leckstrom A, Steiner DF. Effects of beta cell granule components on human islet amyloid polypeptide fibril formation. FEBS Lett. 1996;379:203–6.PubMedCrossRef
51.
• Rickels MR, Collins HW, Naji A. Amyloid and transplanted islets. N Engl J Med. 2008;359:2729–31. This letter provides data that islet transplant recipients may release disproportionately increased islet amyloid polypeptide relative to insulin during hyperglycemia, providing a potential mechanism for the reports of observed amyloid deposition.PubMedCrossRef
52.
• Liu C, Koeberlein B, Feldman MD, et al. Accumulation of intrahepatic islet amyloid in a nonhuman primate transplant model. Endocrinology. 2012;153:1673–83. This study involving a non-human primate model of islet transplantation documents the accumulation of intraheptic islet amyloid over time as a non-immunologic mechanism of islet β-cell loss predating the recurrence of hyperglycemia.PubMedCrossRef
53.
The CITR Research Group. 2007 update on allogeneic islet transplantation from the Collaborative Islet Transplant Registry (CITR). Cell Transplant. 2009;18:753–67.CrossRef
54.
• Koh A, Senior P, Salam A, et al. Insulin-heparin infusions peritransplant substantially improve single-donor clinical islet transplant success. Transplantation. 2010;89:465–71. By multivariate analysis, this retrospective study identified the introduction of the practice of peri-transplant glycemic and anti-thrombotic therapy with infusions of insulin and heparin as significantly associated with the achievement of insulin-independence following transplantation of islets isolated from a single donor.PubMedCrossRef
55.
Hering BJ, Kandaswamy R, Ansite JD, et al. Single-donor, marginal-dose islet transplantation in patients with type 1 diabetes. JAMA. 2005;293:830–5.PubMedCrossRef
56.
Bellin MD, Kandaswamy R, Parkey J, et al. Prolonged insulin independence after islet allotransplants in recipients with type 1 diabetes. Am J Transplant. 2008;8:2463–70.PubMedCrossRef
57.
•• Bellin MD, Barton FB, Heitman A, et al. Potent induction immunotherapy promotes long-term insulin independence after islet transplantation in type 1 diabetes. Am J Transplant. 2012;12:1576–83. Using data both from Minneapolis and the Collaborative Islet Transplant Registry, this analysis indicates that potent T-cell induction therapy with anti-CD3 or a depleting antibody (anti-thymocyte globulin or alemtuzumab) is associated with insulin-independence rate of 50% at 5 years, significantly more than that seen with use of an IL-2 receptor antagonist (as in the Edmonton protocol) and similar to that presently achieved by pancreas alone transplantation. Importantly, the addition of a TNF-α inhibitor (eg, etanercept) was necessary with use of a depleting antibody to have a beneficial effect.
58.
Rickels MR, Chiou AJ, Fuller C, et al. Beta-cell secretory capacity after human islet transplantation by the CIT07 vs Edmonton protocol: preliminary results [abstract]. Am J Transplant. 2011;11 Suppl 2:79–80.
59.
Faradji RN, Tharavanij T, Messinger S, et al. Long-term insulin independence and improvement in insulin secretion after supplemental islet infusion under exenatide and etanercept. Transplantation. 2008;86:1658–65.PubMedCrossRef
60.
Farilla L, Bulotta A, Hirshberg B, et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology. 2003;144:5149–58.PubMedCrossRef
61.
Gangemi A, Salehi P, Hatipoglu B, et al. Islet transplantation for brittle type 1 diabetes: The UIC Protocol. Am J Transplant. 2008;8:1–12.CrossRef
62.
Al Ghofaili K, Fung M, Ao ZL, et al. Effect of exenatide on beta cell function after islet transplantation in type 1 diabetes. Transplantation. 2007;83:24–8.PubMedCrossRef
63.
Froud T, Faradji RN, Pileggi A, et al. The use of exenatide in islet transplant recipients with chronic allograft dysfunction: safety, efficacy, and metabolic effects. Transplantation. 2008;86:36–45.PubMedCrossRef
64.
• Rickels MR, Mueller R, Markman JF, Naji A. Effect of GLP-1 on beta- and alpha-cell function in isolated islet and whole pancreas transplant recipients. J Clin Endocrinol Metab. 2009;94:181–9. This study demonstrated that infusion of the incretin hormone glucagon-like peptide-1 (GLP-1) induced enhancement of glucose-dependent insulin secretion in islet and pancreas transplant recipients, an effect that was dependent on the functional β-cell mass, and also was associated with increased proinsulin secretory ratios that may be associated with depletion of mature β-cell granules.PubMedCrossRef
65.
Tan M, Kandaswamy R, Sutherland DE, Gruessner RW, Gruessner AC, Humar A. Risk factors and impact of delayed graft function after pancreas transplants. Am J Transplant. 2004;4:758–62.PubMedCrossRef
66.
Diem P, Abid M, Redmon JB, Sutherland DER, Robertson RP. Systemic venous drainage of pancreas allografts as independent cause of hyperinsulinemia in type-I diabetic recipients. Diabetes. 1990;39:534–40.PubMedCrossRef
67.
Teuscher AU, Seaquist ER, Robertson RP. Diminished insulin secretory reserve in diabetic pancreas transplant and nondiabetic kidney transplant recipients. Diabetes. 1994;43:593–8.PubMedCrossRef
68.
Cottrell DA. Normalization of insulin sensitivity and glucose homeostasis in type I diabetic pancreas transplant recipients: A 48-month cross-sectional study–a clinical research center study. J Clin Endocrinol Metab. 1996;81:3513–9.PubMedCrossRef
69.
Midtvedt K, Hjelmesaeth J, Hartmann A, et al. Insulin resistance after renal transplantation: The effect of steroid dose reduction and withdrawal. J Am Soc Nephrol. 2004;15:3233–9.PubMedCrossRef
70.
Gillard P, Vandemeulebroucke E, Keymeulen B, et al. Functional beta-cell mass and insulin sensitivity is decreased in insulin-independent pancreas-kidney recipients. Transplantation. 2009;87:402–7.PubMedCrossRef
71.
Robertson RP, Lanz KJ, Sutherland DE, Seaquist ER. Relationship between diabetes and obesity 9 to 18 years after hemipancreatectomy and transplantation in donors and recipients. Transplantation. 2002;73:736–41.PubMedCrossRef
72.
Heller SR, Choudhary P, Davies C, et al. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia. 2007;50:1140–7.CrossRef
73.
Gerich JE, Langlois M, Noacco C, Karam JH, Forsham PH. Lack of glucagon response to hypoglycemia in diabetes: evidence for an intrinsic pancreatic alpha cell defect. Science. 1973;182:171–3.PubMedCrossRef
74.
Cooperberg BA, Cryer PE. Insulin reciprocally regulates glucagon secretion in humans. Diabetes. 2010;59:2936–40.PubMedCrossRef
75.
76.
Pedersen-Bjergaard U, Pramming S, Heller SR, et al. Severe hypoglycaemia in 1076 adult patients with type 1 diabetes: influence of risk markers and selection. Diabetes Metab Res Rev. 2004;20:479–86.PubMedCrossRef
77.
Cryer PE. Mechanisms of hypoglycemia-associated autonomic failure and its component syndromes in diabetes. Diabetes. 2005;54:3592–601.PubMedCrossRef
78.
Fanelli CG, Epifano L, Rambotti AM, et al. Meticulous prevention of hypoglycemia normalizes the glycemic thresholds and magnitude of most of neuroendocrine responses to, symptoms of, and cognitive function during hypoglycemia in intensively treated patients with short-term IDDM. Diabetes. 1993;42:1683–9.PubMedCrossRef
79.
Cranston I, Lomas J, Maran A, Macdonald I, Amiel SA. Restoration of hypoglycemia awareness in patients with long-duration insulin-dependent diabetes. Lancet. 1994;344:283–7.PubMedCrossRef
80.
Dagogojack S, Rattarasarn C, Cryer PE. Reversal of hypoglycemia unawareness, but not defective glucose counter-regulation, in IDDM. Diabetes. 1994;43:1426–34.CrossRef
81.
Rickels MR, Schutta MH, Mueller R, et al. Islet cell hormonal responses to hypoglycemia after human islet transplantation for type 1 diabetes. Diabetes. 2005;54:3205–11.PubMedCrossRef
82.
Kendall DM, Teuscher AU, Robertson RP. Defective glucagon secretion during sustained hypoglycemia following successful islet allo- and autotransplantation in humans. Diabetes. 1997;46:23–7.PubMedCrossRef
83.
Paty BW, Ryan EA, Shapiro AMJ, Lakey JRT, Robertson RP. Intrahepatic islet transplantation in type 1 diabetic patients does not restore hypoglycemic hormonal counter-regulation or symptom recognition after insulin independence. Diabetes. 2002;51:3428–34.PubMedCrossRef
84.
Diamond MP, Hallarman L, Starickzych K, et al. Suppression of counter-regulatory hormone response to hypoglycemia by insulin per se. J Clin Endocrinol Metab. 1991;72:1388–90.PubMedCrossRef
85.
Rickels MR, Schutta MH, Mueller R, et al. Glycemic thresholds for activation of counter-regulatory hormone and symptom responses in islet transplant recipients. J Clin Endocrinol Metab. 2007;92:873–9.PubMedCrossRef
86.
Paty BW, Senior PA, Lakey JR, Shapiro AM, Ryan EA. Assessment of glycemic control after islet transplantation using the continuous glucose monitor in insulin-independent vs insulin-requiring type 1 diabetes subjects. Diabetes Technol Ther. 2006;8:165–73.PubMedCrossRef
87.
Heller SR, Cryer PE. Reduced neuroendocrine and symptomatic responses to subsequent hypoglycemia after 1 episode of hypoglycemia in nondiabetic humans. Diabetes. 1991;40:223–6.PubMedCrossRef
88.
Meyer C, Hering BJ, Grossmann R, et al. Improved glucose counter-regulation and autonomic symptoms after intraportal islet transplants alone in patients with long-standing type I diabetes mellitus. Transplantation. 1998;66:233–40.PubMedCrossRef
89.
Rickels MR, Cullison K, Fuller C, et al. Improvement of glucose counter-regulation following human islet transplantation in long-standing type 1 diabetes: preliminary results [abstract]. Diabetes. 2011;60 Suppl 1:293–OR.
90.
Luzi L, Battezzati A, Perseghin G, et al. Lack of Feedback Inhibition of Insulin-Secretion in Denervated Human Pancreas. Diabetes. 1992;41:1632–9.PubMedCrossRef
91.
Kendall DM, Rooney DP, Smets YFC, Bolding LS, Robertson RP. Pancreas transplantation restores epinephrine response and symptom recognition during hypoglycemia in patients with long-standing type I diabetes and autonomic neuropathy. Diabetes. 1997;46:249–57.PubMedCrossRef
92.
Bolinder J, Wahrenberg H, Persson A, et al. Effect of pancreas transplantation on glucose counter-regulation in insulin-dependent diabetic-patients prone to severe hypoglycemia. J Intern Med. 1991;230:527–33.PubMedCrossRef
93.
Boden G, Chen XH, Desantis R, Kolaczynski J, Morris M. Evidence that suppression of insulin-secretion by insulin itself is neurally-mediated. Metab Clin Exp. 1993;42:786–9.PubMedCrossRef
94.
Gardemann A, Jungermann K, Grosse V, et al. Intraportal transplantation of pancreatic-islets into livers of diabetic rats - reinnervation of islets and regulation of insulin-secretion by the hepatic sympathetic-nerves. Diabetes. 1994;43:1345–52.PubMedCrossRef
95.
Diem P, Redmon JB, Abid M, et al. Glucagon, catecholamine and pancreatic-polypeptide secretion in type-I diabetic recipients of pancreas allografts. J Clin Invest. 1990;86:2008–13.PubMedCrossRef
96.
Battezzati A, Luzi L, Perseghin G, et al. Persistence of counter-regulatory abnormalities in insulin-dependent diabetes-mellitus after pancreas transplantation. Eur J Clin Invest. 1994;24:751–8.PubMedCrossRef
97.
Paty BW, Lanz K, Kendall DM, Sutherland DER, Robertson RP. Restored hypoglycemic counter-regulation is stable in successful pancreas transplant recipients for up to 19 years after transplantation. Transplantation. 2001;72:1103–7.PubMedCrossRef
98.
Hoeldtke RD, Boden G, Shuman CR, Owen OE. Reduced epinephrine secretion and hypoglycemia unawareness in diabetic autonomic neuropathy. Ann Intern Med. 1982;96:459–62.PubMed
99.
Meyer C, Grossmann R, Mitrakou A, et al. Effects of autonomic neuropathy on counter-regulation and awareness at hypoglycemia in type 1 diabetic patients. Diabetes Care. 1998;21:1960–6.PubMedCrossRef
100.
Barrou Z, Seaquist ER, Robertson RP. Pancreas transplantation in diabetic humans normalizes hepatic glucose-production during hypoglycemia. Diabetes. 1994;43:661–6.PubMedCrossRef
Metadata
Title
Recovery of Endocrine Function After Islet and Pancreas Transplantation
Author
Michael R. Rickels
Publication date
01-10-2012
Publisher
Current Science Inc.
Published in
Current Diabetes Reports / Issue 5/2012
Print ISSN: 1534-4827
Electronic ISSN: 1539-0829
DOI
https://doi.org/10.1007/s11892-012-0294-3

Other articles of this Issue 5/2012

Current Diabetes Reports 5/2012 Go to the issue

Treatment of Type 1 Diabetes (D Dabelea, Section Editor)

Continuous Glucose Monitoring in Children and Adolescents

Erratum

Erratum to: Understanding Pancreas Development for β-Cell Repair and Replacement Therapies

Pathogenesis of Type 1 Diabetes (AG Ziegler, Section Editor)

Potential of Pluripotent Stem Cells for Diabetes Therapy

Treatment of Type 1 Diabetes (D Dabelea, Section Editor)

Transition to Adult Care for Youth with Type 1 Diabetes

Transplantation (A Pileggi, Section Editor)

Risks, Benefits, and Therapeutic Potential of Hematopoietic Stem Cell Transplantation for Autoimmune Diabetes

Pathogenesis of Type 1 Diabetes (AG Ziegler, Section Editor)

Anti-Inflammatory Therapy in Type 1 Diabetes
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits